DDRGK1 and metabolic dysfunction-associated steatotic liver disease: Moreover, it is warranted to explore the small-molecule drugs that can enhance the ufmylation on UFBP1, such as protein post-translational modification targeting chimera [68], for the therapeutic management of NAFLD.